AMPHION INNOVATIONS (LON:AMP)
SECTOR – HEALTHCARE
RATING – CORP*
MARKET CAP – £1.36m
CURRENT PRICE – 0.65p
ANALYST – LIAM GASCOIGNE-COHEN |
|
Year-end Dec |
2015A |
2016A |
2017A |
2018E† |
|
Revenue (US$m) |
0.5 |
0.1 |
0.3 |
No
Forecasts |
|
Operating loss (US$m) |
(4.2) |
(3.3) |
(2.9) |
|||
Pre-tax Profit (US$m) |
5.9 |
(16.8) |
2.5 |
|||
EPS (cents) |
3 |
(9) |
1 |
|||
DPS (cents) |
- |
- |
- |
|||
NAV (US$m) |
10.9 |
(5.9) |
(2.8) |
|||
P/E (x) |
- |
- |
- |
|||
Dividend yield (%) |
- |
- |
- |
|||
EV/EBITDA (x) |
- |
- |
- |
|||
|
SOURCE: Northland Capital Partners Limited estimates. Priced at market close. *Northland Capital Partners Limited acts as Joint Broker to Amphion and therefore this information should be viewed as a Marketing Communication. |
Partner Company, WellGen, Finalises License Agreement |
NORTHLAND VIEW |
WellGen is targeting the rapidly growing sports beverage market estimated to reach US$6bn by 2021 (2016 estimate: US$4.6b), according to OrbisResearch.com. Amphion’s other partner companies continue to make progress. Polarean Imaging (POLX.L) is in Phase 3 trials for its novel drug-device platform and Motif Bio (MTFB.L) is awaiting an FDA approval decision for its next generation antibiotic. |
COMPANY DESCRIPTION
Amphion Innovations is an incubator of medical, life science, and technology businesses. |